Perioperative Management of Antisynthetase Syndrome: A Case Report.

J Perianesth Nurs

Department of Anesthesiology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Department of Medical and Surgical Sciences, University of Las Palmas de Gran Canaria, Gran Canaria, Spain.

Published: August 2023

Antisynthetase syndrome is a rare idiopathic inflammatory multisystem disorder, which can lead to serious postoperative complications. Due to its low incidence, there is little literature on its anesthetic management. However, patients with this disease can suffer from serious complications secondary to muscle weakness and respiratory complications. Although the intraoperative and the immediate postoperative periods may be uneventful, complications may appear later. The characteristics of the disease can lead to a misdiagnosis in the case of respiratory acute failure. The objective of this clinical report is to discuss the perioperative management of patients suffering from antisynthetase syndrome, assess the usefulness of postoperative monitoring, and evaluate alternatives that could have been carried out to prevent the fatal outcome reported in this narrative.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jopan.2022.10.009DOI Listing

Publication Analysis

Top Keywords

antisynthetase syndrome
12
perioperative management
8
management patients
8
management antisynthetase
4
syndrome case
4
case report
4
report antisynthetase
4
syndrome rare
4
rare idiopathic
4
idiopathic inflammatory
4

Similar Publications

The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment.

Front Pharmacol

December 2024

Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.

CAR-T cell therapy, a cutting-edge cellular immunotherapy with demonstrated efficacy in treating hematologic malignancies, also exhibits significant promise for addressing autoimmune diseases. This innovative therapeutic approach holds promise for achieving long-term remission in autoimmune diseases, potentially offering significant benefits to affected patients. Current targets under investigation for the treatment of these conditions include CD19, CD20, and BCMA, among others.

View Article and Find Full Text PDF

Objective: To summarize the clinical characteristics of 57 patients diagnosed with anti-glycyl tRNA synthetase (anti-EJ) positive antisynthetase syndrome (ASS), a subtype of anti-glycyl tRNA positive ASS, complicated by interstitial lung disease (ILD), and to investigate the factors asso-ciated with ILD recurrence.

Methods: A retrospective analysis was conducted on the clinical data of 57 anti-EJ positive ASS patientswho were treated at the First Affiliated Hospital of Nanjing Medical University from January 1, 2020 to June 30, 2024. The data collected included demographic information, clinical characteristics, laboratory test results, chest CT findings, and pulmonary function tests.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to examine the clinical and immune system characteristics of patients with anti-synthetase syndrome (ASS) who also have rheumatoid arthritis (RA) compared to those without RA.
  • - Out of 104 ASS patients with arthritis, 23.1% were diagnosed with RA and displayed notable differences such as higher rates of rapidly progressive interstitial lung disease, more tender and swollen joints, and increased bone erosion compared to the non-RA group.
  • - The overlap group (ASS with RA) also had significantly altered immune cell profiles, including decreased regulatory T cells and B cells, as well as higher levels of certain inflammatory markers, leading to a lower rate of complete clinical response.
View Article and Find Full Text PDF

Idiopathic inflammatory myopathies related lung disease in adults.

Lancet Respir Med

November 2024

Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, USA.

Article Synopsis
  • Interstitial lung disease (ILD) frequently occurs in adults with idiopathic inflammatory myopathies, particularly those with antisynthetase syndrome and anti-MDA5 antibodies, manifesting in various severities from mild to rapidly worsening symptoms.
  • Common symptoms include lung issues along with myositis, skin lesions, arthritis, and Raynaud’s phenomenon, but 16-65% may have lung problems as the only indication.
  • Treatment typically involves immunosuppression, combining therapies for aggressive cases, and possibly lung transplantation for severe cases, although short-term mortality is notably high in rapidly progressive disease associated with anti-MDA5 antibodies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!